CARLSMED, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
CARL$14.71-8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED BALANCE SHEETS
(in thousands, except for share and par value amounts)
(unaudited)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $35,945 | $85,793 |
| Restricted cash | 100 | 100 |
| Short-term investments | 24,000 | 24,000 |
| Marketable securities | 20,262 | — |
| Accounts receivable, net of allowances of $1,495 and $1,653, as of September 30, 2026 and December 31, 2025, respectively | 16,884 | 11,362 |
| Inventory | 2,987 | 1,845 |
| Prepaid expenses and other current assets | 5,377 | 3,573 |
| Total current assets | 105,555 | 126,673 |
| Property and equipment, net | 3,611 | 1,487 |
| Operating lease right-of-use assets | 5,707 | 1,826 |
| Other assets | 397 | 134 |
| Total assets | $115,270 | $130,120 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,311 | $4,481 |
| Accrued liabilities | 6,766 | 3,287 |
| Accrued compensation | 7,371 | 5,760 |
| Short-term operating lease liabilities | 789 | 752 |
| Total current liabilities | 18,237 | 14,280 |
| Long-term portion of term loan, net | 15,400 | 15,346 |
| Long-term operating lease liabilities | 5,596 | 1,316 |
| Other long-term liabilities | 363 | 309 |
| Total liabilities | 39,596 | 31,251 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.00001 par value; 10,000,000 shares authorized and zero shares issued and outstanding as of September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.00001 par value; 600,000,000 shares authorized and 27,387,646 shares issued and outstanding as of September 30, 2026; 600,000,000 shares authorized, 26,664,243 shares issued, and 26,604,505 shares outstanding as of December 31, 2025 | — | — |
| Additional paid-in capital | 207,968 | 199,674 |
| Accumulated deficit | (132,256) | (100,805) |
| Accumulated other comprehensive loss | (38) | — |
| Total stockholders’ equity | 75,674 | 98,869 |
| Total liabilities and stockholders’ equity | $115,270 | $130,120 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.